Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Blinded Reference Set for Multicancer Early Detection Blood Tests

NCT05334069 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT05334069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05334069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Blinded Reference Set for Multicancer Early Detection Blood Tests
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Observational
Overall status
Recruiting
Start date
August 18, 2022
Completion date
February 28, 2027
Enrollment
2,000 (estimated)
Sites
747

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myeloid leukemia, ann arbor stage i lymphoma, ann arbor stage ii lymphoma, ann arbor stage iii lymphoma, ann arbor stage iv lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, gastroesophageal junction adenocarcinoma, head and neck carcinoma, hematopoietic and lymphoid cell neoplasm, invasive breast carcinoma, kidney carcinoma, malignant hepatobiliary neoplasm, malignant solid neoplasm, melanoma, muscle-invasive bladder carcinoma, riss stage i plasma cell myeloma, riss stage ii plasma cell myeloma, riss stage iii plasma cell myeloma, sarcoma, stage i bladder cancer ajcc v6 and v7, stage i breast cancer ajcc v7, stage i colorectal cancer ajcc v6 and v7, stage i esophageal cancer ajcc v7, stage i gastric cancer ajcc v7, stage i lung cancer ajcc v7, stage i ovarian cancer ajcc v6 and v7, stage i pancreatic cancer ajcc v6 and v7, stage i prostate cancer ajcc v7, stage i uterine corpus cancer ajcc v7, stage ii bladder cancer ajcc v6 and v7, stage ii breast cancer ajcc v6 and v7, stage ii colorectal cancer ajcc v7, stage ii esophageal cancer ajcc v7, stage ii gastric cancer ajcc v7, stage ii lung cancer ajcc v7, stage ii ovarian cancer ajcc v6 and v7, stage ii pancreatic cancer ajcc v6 and v7, stage ii prostate cancer ajcc v7, stage ii uterine corpus cancer ajcc v7, stage iii bladder cancer ajcc v6 and v7, stage iii breast cancer ajcc v7, stage iii colorectal cancer ajcc v7, stage iii esophageal cancer ajcc v7, stage iii gastric cancer ajcc v7, stage iii lung cancer ajcc v7, stage iii ovarian cancer ajcc v6 and v7, stage iii pancreatic cancer ajcc v6 and v7, stage iii prostate cancer ajcc v7, stage iii uterine corpus cancer ajcc v7, stage iv bladder cancer ajcc v7, stage iv breast cancer ajcc v6 and v7, stage iv colorectal cancer ajcc v7, stage iv esophageal cancer ajcc v7, stage iv gastric cancer ajcc v7, stage iv lung cancer ajcc v7, stage iv ovarian cancer ajcc v6 and v7, stage iv pancreatic cancer ajcc v6 and v7, stage iv prostate cancer ajcc v7, stage iv uterine corpus cancer ajcc v7, thyroid gland carcinoma